Balance Sheet

v3.8.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2017
Dec. 31, 2016
Current Assets    
Cash and cash equivalents $ 9,763,067 $ 7,842,667
Accounts receivable 14,833 82,305
Prepaid expenses and other current assets 1,967,257 338,049
Total Current Assets 11,745,157 8,263,021
Property and Equipment, net 286,891 359,592
Other Assets    
Restricted cash 2,292 101,171
In-process R&D 5,866,000
Goodwill 2,189,338
Deposits 69,798 69,798
Related party receivable 103,017
Deferred financing costs 30,000
Total Other Assets 8,157,428 273,986
Total Assets 20,189,476 8,896,599
Current Liabilities    
Accounts payable 1,033,680 290,058
Deferred revenue 7,026,388
Accrued expenses and other liabilities 2,276,431 1,305,173
Total Current Liabilities 10,336,499 1,595,231
Long Term Liabilities    
Other long-term liabilities 160,559 461,434
Deferred tax liability 1,302,220
Contingent consideration 2,609,289
Total Liabilities 14,408,567 2,056,665
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 4,200,310 and 2,620,439 issued and outstanding at December 31, 2017 and 2016, respectively 840 524
Additional paid-in capital 76,382,262 65,872,943
Accumulated deficit (68,846,326) (57,004,655)
Accumulated other comprehensive loss (166,025) (72,231)
Total Stockholders' Equity - Heat Biologics, Inc 7,370,751 8,796,581
Non-Controlling Interest (1,589,842) (1,956,647)
Total Stockholders' Equity 5,780,909 6,839,934
Total Liabilities and Stockholders' Equity $ 20,189,476 $ 8,896,599

Source